Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF INDIA AND EUROPE GENERIC INJECTABLE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 YEARS CONSIDERED FOR THE STUDY
2.3 CURRENCY AND PRICING
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 INDIA MULTIVARIATE MODELLING
2.6 TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 VENDOR SHARE ANALYSIS
2.9 SECONDARY SOURCES
2.1 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.1.1 EUROPE
4.1.2 INDIA
4.2 PORTER FIVE FORCED
4.2.1 EUROPE
4.2.2 INDIA
4.3 EPIDEMIOLOGY
5 EUROPE GENERIC INJECATBLE MARKET OVERVIEW
5.1 DRIVERS
5.1.1 SURGE IN DEVELOPMENT AND PRODUCTION OF GENERIC INJECTABLE
5.1.2 PIONEERING PROGRESS FUELED BY TECHNOLOGICAL ADVANCEMENTS IN DRUG MOLECULES
5.1.3 SURGE OF GENERIC INJECTABLE MARKET AMIDST THE ESCALATING PREVALENCE OF CHRONIC DISEASES
5.2 RESTRAINTS
5.2.1 ENSURING AND MAINTAINING HIGH-QUALITY STANDARDS
5.2.2 ENSURING THE QUALIFICATION AND ETHICAL STANDARDS OF A CONTRACT MANUFACTURING ORGANIZATION (CMO)
5.2.3 NAVIGATING MARKET CHALLENGES IN THE DEVELOPMENT COSTS OF GENERIC INJECTABLE
5.3 OPPORTUNITIES
5.3.1 ASCENDANCE OF MARKET GROWTH THROUGH INCREASED EMPHASIS ON CONTRACT RESEARCH MANUFACTURING
5.3.2 SYNERGIZING INNOVATION THROUGH COLLABORATIVE DRUG RESEARCH AND DEVELOPMENT
5.3.3 EXPANSION IN MARKET GROWTH FUELED BY RISING PREFERENCE FOR GENERIC DRUGS OVER NOVEL ALTERNATIVES
5.3.4 EXPANDING HORIZONS PROPELLED BY GROWING PIPELINE OF INNOVATIVE PRODUCTS
5.4 CHALLENGES
5.4.1 LOGISTICAL CHALLENGES DUE TO SPECIALIZED STORAGE AND TRANSPORTATION NEEDS
6 INDIA GENERIC INJECATBLE MARKET OVERVIEW
6.1 DRIVERS
6.1.1 ESCALATING INCIDENCE OF CHRONIC DISEASES
6.1.2 DEPENDENCE ON THE INDIAN MANUFACTURERS FOR GENERIC VERSION
6.1.3 AVAILABILITY OF A WIDE VARIETY OF DISTRIBUTION CHANNELS
6.2 RESTRAINTS
6.2.1 ELEVATED STANDARDS OF QUALITY ASSURANCE IN GENERIC INJECTABLE
6.3 OPPORTUNITIES
6.3.1 MARKET EXPANSION SURGING WITH A HEIGHTENED FOCUS ON CONTRACT RESEARCH MANUFACTURING ORGANIZATION
6.3.2 HARMONIZING INNOVATION BY COLLABORATIVE EFFORTS IN DRUG RESEARCH AND DEVELOPMENT
6.3.3 MARKET GROWTH EXPANDS DUE TO INCREASING FAVOR FOR GENERIC DRUGS INSTEAD OF NOVEL ALTERNATIVES
6.3.4 GOVERNMENT DRIVE AND ADVOCACY FOR GENERIC MEDICATIONS
6.4 CHALLENGES
6.4.1 CHALLENGES IN LOGISTICS ARISING FROM SPECIALIZED STORAGE AND TRANSPORTATION REQUIREMENTS
7 INDIA & EUROPE INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION
7.1 OVERVIEW
7.2 ONCOLOGY
7.3 CARDIOVASCULAR DISORDERS
7.4 INFECTIOUS DISEASES
7.5 PAIN MANAGEMENT
7.6 METABOLIC DISORDERS (DIABETES)
7.7 IMMUNOLOGY DISORDERS
8 INDIA & EUROPE INJECTABLE DRUG DELIVERY MARKET, BY BIOSIMILAR DRUGS
8.1 OVERVIEW
8.2 SEMAGLUTIDE
8.3 IBUTILIDE FUMARATE
8.4 EVOLOCUMAB
8.5 ALIROCUMAB
8.6 ANIDULAFUNGIN
8.7 DULAGLUTIDE
8.8 LIXISENATIDE
8.9 EXENATIDE
8.1 LIRAGLUTIDE
8.11 ADALIMUMAB
9 INDIA & EUROPE INJECTABLE DRUG DELIVERY MARKET, BY END USER
9.1 OVERVIEW
9.2 DIRECT SALES DISTRIBUTORS
9.3 PHARMACEUTICAL WHOLESALERS
9.4 DRUG STORES
9.5 PHARMACY
9.6 GROUP PURCHASING ORGANIZATIONS (GPOS)
9.7 OTHERS
10 INDIA & EUROPE INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 CONTRACT MANUFACTURERS
10.3 PHARMACEUTICAL WHOLESALERS
10.4 PHARMACY CHAINS
10.5 GROUP PURCHASING ORGANIZATIONS (GPOS)
10.6 OTHERS
11 INDIA AND EUROPE GENERIC INJECTABLE MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: EUROPE
11.2 COMPANY SHARE ANALYSIS: INDIA
12 SWOT ANALYSIS
12.1 CONTRACT MANUFACTURERS
12.2 MANUFACTURERS
12.3 DISTRIBUTORS
13 COMPANY PROFILE (CONTRACT MANUFACTURERS)
13.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.1.1 COMPANY SNAPSHOT
13.1.2 PRODUCT PORTFOLIO
13.1.3 RECENT DEVELOPMENT
13.2 CARDINAL HEALTH
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENT
13.3 DIVI'S LABORATORIES LIMITED.
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 PRODUCT PORTFOLIO
13.3.4 RECENT DEVELOPMENT
13.4 DR. REDDY’S LABORATORIES LTD
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENT
13.5 FAREVA
13.5.1 COMPANY SNAPSHOT
13.5.2 PRODUCT PORTFOLIO
13.5.3 RECENT DEVELOPMENT
13.6 HIKMA PHARMACEUTICALS PLC
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 INNOVEXIA LIFESCIENCES PVT LTD
13.7.1 COMPANY SNAPSHOT
13.7.2 PRODUCT PORTFOLIO
13.7.3 RECENT DEVELOPMENT
13.8 MEDLOCK HEALTHCARE
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENT
13.9 RECIPHARM AB.
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 SWISSCHEM
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.11.1 COMPANY SNAPSHOT
13.11.2 REVENUE ANALYSIS
13.11.3 PRODUCT PORTFOLIO
13.11.4 RECENT DEVELOPMENT
13.12 VENUS PHARMA GMBH.
13.12.1 COMPANY SNAPSHOT
13.12.2 PRODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENT
13.13 ZYDUS GROUP
13.13.1 COMPANY SNAPSHOT
13.13.2 REVENUE ANALYSIS
13.13.3 PRODUCT PORTFOLIO
13.13.4 RECENT DEVELOPMENT
14 COMPANY PROFILES (DISTRIBUTORS)
14.1 AAH PHARMACEUTICALS LTD
14.1.1 COMPANY SNAPSHOT
14.1.2 PRODUCT DESCRIPTION
14.1.3 RECENT DEVELOPMENT
14.2 HENRY SCHEIN, INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 MAWDSLEYS – BROOKS & CO. LTD.
14.3.1 COMPANY SNAPSHOT
14.3.2 PRODUCT DESCRIPTION
14.3.3 RECENT DEVELOPMENT
14.4 MEDLINE INDUSTRIES, LP.
14.4.1 COMPANY SNAPSHOT
14.4.2 PRODUCT PORTFOLIO
14.4.3 RECENT DEVELOPMENT
15 COMPANY PROFILES (GENERIC MANUFACTURERS)
15.1 FRESENIUS SE & CO. KGAA
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 AMNEAL PHARMACEUTICALS LLC
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 LUPIN.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 ZYDUS GROUP
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 AUROBINDO PHARMA.
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.7 CIPLA INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 CONCORD BIOTECH.
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 DR. REDDY’S LABORATORIES LTD
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 GLAND PHARMA LIMITED
15.10.1 COMPANY SNAPSHOT
15.10.2 SOURCE: COMPANY WEBSITE, ANNUAL REPORTS, AND SEC FILING
15.10.3 REVENUE ANALYSIS
15.10.4 PRODUCT PORTFOLIO
15.10.5 RECENT DEVELOPMENT
15.11 GLENMARK PHARMACEUTICALS LTD
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 HIKMA PHARMACEUTICALS PLC
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 INTAS PHARMACEUTICALS LTD.
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 PAR PHARMACEUTICAL.
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 SANDOZ GROUP AG
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 SANOFI
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 VIATRIS INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
18 REFERENCES
List of Table
TABLE 1 INDIA GENERIC INJECTABLE MARKET, BY THERAPEUTIC APPLICATION, 2022-2035 (USD MILLION)
TABLE 2 EUROPE GENERIC INJECTABLE MARKET, BY THERAPEUTIC APPLICATION, 2022-2035 (USD MILLION)
TABLE 3 EUROPE ONCOLOGY IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 4 EUROPE ONCOLOGY IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 5 EUROPE CARDIOVASCULAR DISORDERS IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 6 INDIA CARDIOVASCULAR DISORDERS IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 7 EUROPE INFECTIOUS DISEASES IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 8 INDIA INFECTIOUS DISEASES IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 9 EUROPE PAIN MANAGEMENT IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 10 INDIA PAIN MANAGEMENT IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 11 EUROPE METABOLIC DISORDERS (DIABETES) IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 12 INDIA METABOLIC DISORDERS (DIABETES) IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 13 EUROPE IMMUNOLOGY IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 14 INDIA IMMUNOLOGY IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION)
TABLE 15 EUROPE GENERIC INJECTABLE MARKET, BY BIOSIMILAR DRUGS, 2022-2035 (USD MILLION)
TABLE 16 INDIA GENERIC INJECTABLE MARKET, BY BIOSIMILAR DRUGS, 2022-2035 (USD MILLION)
TABLE 17 EUROPE GENERIC INJECTABLE MARKET, BY END USER, 2022-2035 (USD MILLION)
TABLE 18 INDIA GENERIC INJECTABLE MARKET, BY END USER, 2022-2035 (USD MILLION)
TABLE 19 EUROPE GENERIC INJECTABLE MARKET, BY END USER, 2022-2035 (USD MILLION)
TABLE 20 INDIA GENERIC INJECTABLE MARKET, BY END USER, 2022-2035 (USD MILLION)
TABLE 21 EUROPE GENERIC INJECTABLE MARKET, BY DISTRIBUTION CHANNEL, 2022-2035 (USD MILLION)
TABLE 22 INDIA GENERIC INJECTABLE MARKET, BY DISTRIBUTION CHANNEL, 2022-2035 (USD MILLION)
List of Figure
FIGURE 1 INDIA AND EUROPE GENERIC INJECTABLE MARKET: SEGMENTATION
FIGURE 2 INDIA AND EUROPE GENERIC INJECTABLE MARKET: DATA TRIANGULATION
FIGURE 3 INDIA GENERIC INJECTABLE MARKET: DROC ANALYSIS
FIGURE 4 EUROPE GENERIC INJECTABLE MARKET: DROC ANALYSIS
FIGURE 5 INDIA GENERIC INJECTABLE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 6 EUROPE GENERIC INJECTABLE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 7 INDIA AND EUROPE GENERIC INJECTABLE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 8 EUROPE MULTIVARIATE MODELLING
FIGURE 9 INDIA AND EUROPE GENERIC INJECTABLE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 10 INDIA AND EUROPE GENERIC INJECTABLE MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 INDIA AND EUROPE GENERIC INJECTABLE MARKET: SEGMENTATION
FIGURE 12 ESCALATING INCIDENCE OF CHRONIC DISEASES AND SURGE IN THE DEVELOPMENT AND PRODUCTION OF GENERIC INJECTABLE IS DRIVING THE GROWTH OF THE INDIA GENERIC INJECTABLE MARKET IN THE FORECAST PERIOD OF 2024 TO 2035
FIGURE 13 SURGE IN DEVELOPMENT AND PRODUCTION OF GENERIC INJECTABLE DRUGS IS EXPECTED TO DRIVE THE EUROPEAN GENERIC INJECTABLE MARKET IN THE FORECAST PERIOD OF 2024 TO 2035
FIGURE 14 ONCOLOGY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE INDIA GENERIC INJECTABLE MARKET IN 2024 AND 2035
FIGURE 15 ONCOLOGY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE GENERIC INJECTABLE MARKET IN 2024 AND 2035
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE GENERIC INJECATBLE MARKET
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF INDIA GENERIC INJECATBLE MARKET
FIGURE 18 EUROPE GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, 2023
FIGURE 19 EUROPE GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, 2024-2035 (USD MILLION)
FIGURE 20 EUROPE GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, CAGR (2024-2035)
FIGURE 21 EUROPE GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE
FIGURE 22 INDIA GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, 2023
FIGURE 23 INDIA GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, 2024-2035 (USD MILLION)
FIGURE 24 INDIA GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, CAGR (2024-2035)
FIGURE 25 INDIA GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE
FIGURE 26 EUROPE GENERIC INJECTABLE MARKET: BY BIOSIMILAR DRUGS, 2023
FIGURE 27 EUROPE GENERIC INJECTABLE MARKET: BY BIOSIMILAR DRUGS, 2024-2035 (USD MILLION)
FIGURE 28 INDIA GENERIC INJECTABLE MARKET: BY BIOSIMILAR DRUGS, 2023
FIGURE 29 INDIA GENERIC INJECTABLE MARKET: BY BIOSIMILAR DRUGS, 2024-2035 (USD MILLION)
FIGURE 30 EUROPE GENERIC INJECTABLE MARKET: BY END USER, 2023
FIGURE 31 EUROPE GENERIC INJECTABLE MARKET: BY END USER, 2024-2035 (USD MILLION)
FIGURE 32 EUROPE GENERIC INJECTABLE MARKET: BY END USER, CAGR (2024-2035)
FIGURE 33 EUROPE GENERIC INJECTABLE MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 INDIA GENERIC INJECTABLE MARKET: BY END USER, 2023
FIGURE 35 INDIA GENERIC INJECTABLE MARKET: BY END USER, 2024-2035 (USD MILLION)
FIGURE 36 INDIA GENERIC INJECTABLE MARKET: BY END USER, CAGR (2024-2035)
FIGURE 37 INDIA GENERIC INJECTABLE MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 39 EUROPE GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, 2024-2035 (USD MILLION)
FIGURE 40 EUROPE GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2035)
FIGURE 41 EUROPE GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 INDIA GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 43 INDIA GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, 2024-2035 (USD MILLION)
FIGURE 44 INDIA GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2035)
FIGURE 45 INDIA GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 EUROPE GENERIC INJECTABLE MARKET: COMPANY SHARE 2023 (%)
FIGURE 47 INDIA GENERIC INJECTABLE MARKET: COMPANY SHARE 2023 (%)
